Back to Journals » OncoTargets and Therapy » Volume 9

Long noncoding RNA AFAP1-AS1, a potential novel biomarker to predict the clinical outcome of cancer patients: a meta-analysis

Authors Liu F, Xue Q, Zhu P, Luo H, Zhang Y, Hao T

Received 25 February 2016

Accepted for publication 7 May 2016

Published 12 July 2016 Volume 2016:9 Pages 4247—4254


Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Ram Prasad

Peer reviewer comments 2

Editor who approved publication: Professor Min Li

Fang-teng Liu,1,* Qi-zhen Xue,2,* Pei-qian Zhu,1 Hong-liang Luo,1 Yi Zhang,1 Tengfei Hao1

1Department of Gastrointestinal Surgery, the Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi Province, 2Institute of Toxicology, College of Preventive Medicine, Third Military Medical University, Chongqing, People’s Republic of China

*These authors contributed equally to this paper

Abstract: A number of studies have demonstrated that the expression level of actin filament-associated protein 1 antisense RNA 1 (AFAP1-AS1) was upregulated in various cancers. High expression of AFAP1-AS1 is associated with an increased risk of metastasis and a poor prognosis in cancer patients. The electronic search was conducted in PubMed, EMBASE, Cochrane Library, China National Knowledge Infrastructure, and Wanfang database. We collected relevant articles to explore the association between the expression levels of AFAP1-AS1 and lymph node metastasis, distant metastasis, overall survival, relapse-free survival, and progression-free survival. A total of 1,017 patients from eight studies were finally included. The results showed that cancer patients with high AFAP1-AS1 expression suffered an increased risk of developing lymph node metastasis (odds ratio =3.19, 95% confidence interval [CI]: 2.11–4.83, P<0.00001) and distant metastasis (odds ratio =3.05, 95% CI: 1.84–5.04, P<0.0001). Moreover, we found that patients with high AFAP1-AS1 expression also had a poorer overall survival (hazard ratio [HR]: 1.98, 95% CI: 1.57–2.38, P=0.000), a worse progression-free survival (HR: 1.73, 95% CI: 1.11–2.35, P=0.000), and a shorter recurrence-free survival (HR: 1.96, 95% CI: 1.02–2.90, P=0.000) than those with low AFAP1-AS1 expression. High expression of AFAP1-AS1 was associated with poor clinical outcome. AFAP1-AS1 might serve as a potential novel biomarker for indicating the clinical outcomes in human cancers.

lncRNA, AFAP1-AS1, carcinoma, clinical outcome, meta-analysis

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]